Urological malignancies in kidney transplant recipient patients

Abstract

Kidney transplantation is now established as the ideal treatment option for end-stage renal disease (ESRD) and renal cell carcinoma (RCC) patients. Since the first kidney transplant in the 1970s, research has allowed us to understand the long term sequelae of kidney transplant patients (TXPs) including the risks of increased malignancy from immunosuppression.